Names and pronunciation
(boe-sue′ti-nib) Bosulif
PDF page 183
Loading InternPractice…
Drug reference
(boe-sue′ti-nib) Bosulif
PDF page 183
Func. class.: Antineoplastic biologic response modifiers
PDF page 183
Chem. class.: Signal transduction in- hibitors (STIs), tyrosine kinase inhibitor
PDF page 183
USES: Treatment of CML (chronic accelerator phase); Philadelphia chromosome–positive patients in blast- cell crisis Contraindications: Pregnancy, hypersensitivity
PDF page 183
DOSAGE AND ROUTES Newly diagnosed chronic phase PHxCML • Adult: PO 400 mg daily with food, may increase to 600 mg/day in those who have not developed grade 3 toxic- ity or who do not reach complete hematologic response by wk 8 or com- plete cytogenic response (CCyR) by wk 12 Chronic accelerated or blast phase Philadelphia chromosome–positive (PH+) CML B Adult: PO 500 mg daily with food, may use escalation to 600 mg daily in those not reaching hematologic response by wk 8 or complete cytogenia response by wk 12 Hepatic dosage • Adult: PO Any baseline hepatic impair- ment: start at 200 mg/day; liver trans aminase >5 × ULN, hold dose until levels are ≤2.5 × ULN, then resume at 400 mg/ day; liver transaminase level ≥3 × ULN and bilirubin >2 × ULN and alkaline phos- phatase <2 × ULN, discontinue
PDF page 183
Available forms: 100, 400, 500 mg tablets
PDF page 183
• Adult: PO 400 mg daily with food, may increase to 600 mg/day in those who have not developed grade 3 toxic- ity or who do not reach complete hematologic response by wk 8 or com- plete cytogenic response (CCyR) by wk 12 Chronic accelerated or blast phase Philadelphia chromosome–positive (PH+) CML B Adult: PO 500 mg daily with food, may use escalation to 600 mg daily in those not reaching hematologic response by wk 8 or complete cytogenia response by wk 12 Hepatic dosage
PDF page 183
• Adult: PO Any baseline hepatic impair- ment: start at 200 mg/day; liver trans aminase >5 × ULN, hold dose until levels are ≤2.5 × ULN, then resume at 400 mg/ day; liver transaminase level ≥3 × ULN and bilirubin >2 × ULN and alkaline phos- phatase <2 × ULN, discontinue
PDF page 183